share_log

CNS Pharmaceuticals | 8-K: CNS Pharmaceuticals Reports First Quarter 2024 Financial Results Enrollment completed in potentially pivotal GBM study evaluating Berubicin; Topline data expected in first half of 2025

CNS Pharmaceuticals | 8-K: CNS Pharmaceuticals Reports First Quarter 2024 Financial Results Enrollment completed in potentially pivotal GBM study evaluating Berubicin; Topline data expected in first half of 2025

CNS Pharmaceuticals | 8-K:CNS Pharmicals公佈2024年第一季度財務業績評估伯魯比辛的潛在關鍵GBM研究已完成註冊;Topline數據預計將於2025年上半年發佈
美股SEC公告 ·  05/16 10:01
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息